A Clinical Study of SHR-9539 in Patients With Multiple Myeloma

PHASE1RecruitingINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

August 7, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

July 31, 2027

Conditions

Multiple Myeloma

Interventions

DRUG

SHR-9539 for injection

SHR-9539 for dose escalation/dose extension

Trial Locations (1)

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

INDUSTRY